| Popis: |
A non-covalent oral drug targeting severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) main protease (Mpro), ensitrelvir (brand name Xocova), has been developed by Unoh et al. (J. Med. Chem. 2022, 65, 9, 6499–6512) using structure-based drug design (SBDD). To elucidate the factors responsible for the enhanced inhibitory activities from in silico screening hit compound to ensitrelvir, we analyzed interaction energies between the inhibitor and each residue of Mpro using fragment molecular orbital (FMO) calculations. This analysis reveals that functional group conversion for P1’ and P1 parts in the two inhibitors increases the strength of existing interactions with Mpro and also provides novel interactions for ensitrelvir. Moreover, the associated slight changes in the conformation of Mpro induce further interactions for ensitrelvir in other parts, including hydrogen bonds, a halogen bond, and π-orbital interactions. Thus, we shed light on the promising strategies of SBDD for leading ensitrelvir to get higher inhibitory activity against Mpro by elucidating microscopic interactions through FMO-based analysis. These detailed mechanism findings, including water cross-linkings, will give a powerful tool for further improvement in SBDD. |
